Pure Global AI
NCT06275243Recruitment Completed

Polymorphism of ApoE in Alzheimer's Disease: Genetic Study in Castile and Leon (Spain)

Alzheimer's Disease as a Sociosanitary Priority: ApoE Gene Polymorphism
Universidad de LeónClinicalTrials.govdiagnostic test
Verified
Study focus
Disease/Condition
Alzheimer Disease
Drug/Device/Intervention
Kit Buccal swab collection & stabilization de Canvax®
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Universidad de León
Location
León, Spain
Timeline & enrollment
Phase
N/A
Start date
Jul 06, 2022
End date
Mar 22, 2024
Enrollment
511 participants
Primary outcome

Distribution of ApoE variants in the Alzheimer's disease population diagnosed in Castile and Leon.

Summary

The general objective of this randomized and longitudinal clinical study was to estimate the
 frequencies of ApoE variants both in the user population of the Messengers of Peace
 Residences and the Associations of Relatives of Alzheimer's Patients in Castile y Leon,
 since, due to its geographical location at the crossroads, it has received multiple genetic
 contributions from both northern Europe, the Mediterranean area and northern Africa.
 
 The main questions it aims to answer are:
 
 - What are the allelic frequencies of ApoE variants in the population of individuals with
 Alzheimer's disease in Castile and Leon?
 
 - Is there a correlation between the ApoE4 variant and the lipid profile in the blood of
 individuals with Alzheimer's disease in this region?

ICD-10 classifications
Alzheimer diseaseAlzheimer disease, unspecifiedOther Alzheimer diseaseDementia in Alzheimer diseaseDementia in Alzheimer disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06275243
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06275243 through Pure Global AI's free database. This phase not specified trial is sponsored by Universidad de León and is currently Recruitment Completed. The study focuses on Alzheimer Disease. Target enrollment is 511 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.